Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia

Cancer Research

Volumn 64, Issue 24, 2004, Pages 8816-8820

  Bentires Alj, Mohamed ^a,b,l   Paez, J Guillermo ^c   David, Frank S ^a,e   Keilhack, Heike ^a   Halmos, Balazs ^a   Naoki, Katsuhiko ^c   Maris, John M ^d   Richardson, Andrea ^e   Bardelli, Alberto ^f   Sagarbaker, David J ^c   Richards, William G ^e   Du, Jinyan ^g   Girard, Luc ^h   Minna, John D ^h   Loh, Mignon L ⁱ   Fisher, David E ^g   Velculescu, Victor E ^j   Vogelstein, Bert ^j   Meyerson, Matthew ^c   Sellers, William R ^c,k   Neel, Benjamin G ^a   more..

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF TURIN   (Italy)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^l Laboratory of Cancer Biology   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN SH2; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; BREAST CANCER; COLON CANCER; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; JUVENILE MYELOMONOCYTIC LEUKEMIA; LUNG CANCER; MELANOMA; MISSENSE MUTATION; MYELODYSPLASTIC SYNDROME; NEUROBLASTOMA; NOONAN SYNDROME; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SOLID TUMOR; SOMATIC MUTATION;

ADULT; CELL LINE, TUMOR; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MUTATION, MISSENSE; NEOPLASMS; NOONAN SYNDROME; PROTEIN-TYROSINE-PHOSPHATASE; SRC HOMOLOGY DOMAINS;

EID: 10844290923     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1923     Document Type: Article

References (20)

1. Neel BG, Gu H, Pao L. The "Shp"ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 2003;28:284-93.
2. Tartaglia M, Niemeyer CM, Shannon KM, Loh ML. SHP-2 and myeloid malignancies. Curr Opin Hematol 2004;11:44-50.
3. Cotton JL, Williams RG. Noonan syndrome and neuroblastoma. Arch Pediatr Adolesc Med 1995;149:1280-1.
4. Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myetodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003;34:148-50.
5. Loh ML, Vattikuti S, Schubbert S, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2004;103:2325-31.
6. Tartaglia M, Martinelli S, Cazzaniga G, et al. Genetic evidence for lineage- and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 2004;104:307-13.
7. Barford D, Neel BG. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure 1998;6:249-54.
8. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 200l;29:465-8.
9. Bos JL. The ras gene family and human carcinogenesis. Mutat Res 1988;195:255-71.
10. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-5.
11. Bardelli A, Parsons DW, Silliman N, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science (Wash DC) 2003;300:949.
12. Naoki K, Chen TH, Richards WG, Sugarbaker DJ, Meyerson M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002;62:7001-3.
13. Araki T, Mohi MG, Ismat FA, et al. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 2004;10:849-57.
14. Musante L, Kehl HG, Majewski F, et al. Spectrum of mutations in PTPN11 and genotype-phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome. Eur J Hum Genet 2003;11:201-6.
15. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-79.
16. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
17. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer; correlation with clinical response to gefitinib therapy. Science (Wash DC) 2004;304:1497-500.
18. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature (Lond) 2002;417:949-54.
19. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
20. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (Lond) 2002;418:934.